Drug Trial Radar · NCT06896916
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Aug 7, 2025
Primary completion
Mar 2036
Study completion Mar 2036
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.
Conditions
- Multiple Myeloma
Interventions
EtentamigDrug
Intravenous (IV) Infusion
IberdomideDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)Time frame: Up to Approximately 56 Days
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 129 Months
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
Beverly Hills Cancer Center /ID# 266921
Beverly Hills, California · Recruiting
Colorado Blood Cancer Institute /ID# 273751
Denver, Colorado · Recruiting
Washington University /ID# 266972
St Louis, Missouri · Recruiting
Rutgers Cancer Institute of New Jersey /ID# 266833
New Brunswick, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282
New York, New York · Recruiting
University Of North Carolina Health Care - Hillsborough Campus /ID# 278230
Hillsborough, North Carolina · Recruiting
Swedish Medical Center - Seattle /ID# 268052
Seattle, Washington · Recruiting
Blacktown Hospital /ID# 265983
Blacktown, New South Wales, Australia · Recruiting
Wollongong Hospital /ID# 265625
Wollongong, New South Wales, Australia · Recruiting
The Alfred Hospital /ID# 265981
Melbourne, Victoria, Australia · Recruiting
Austin Hospital /ID# 265984
Melbourne, Victoria, Australia · Recruiting
Sir Charles Gairdner Hospital /ID# 265985
Nedlands, Western Australia, Australia · Recruiting
University Health Network_Princess Margaret Cancer Centre /ID# 275636
Toronto, Ontario, Canada · Recruiting
Jewish General Hospital /ID# 267574
Montreal, Quebec, Canada · Recruiting
Chu de Nice-Hopital Larchet Ii /Id# 266845
Nice, Alpes-Maritimes, France · Recruiting
Hôpital La Timone /ID# 267053
Marseille, Bouches-du-Rhone, France · Recruiting
Chu De Lille - Hopital Claude Huriez /ID# 270193
Lille, Hauts-de-France, France · Recruiting
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694
Tours, Indre-et-Loire, France · Recruiting
IUCT Oncopole /ID# 266391
Toulouse, Occitanie, France · Recruiting
National Cancer Center Hospital East /ID# 268343
Kashiwa-shi, Chiba, Japan · Recruiting
Kumamoto University Hospital /ID# 270530
Kumamoto, Kumamoto, Japan · Recruiting
Dokkyo Medical University Hospital /ID# 271648
Mibu, Tochigi, Japan · Recruiting
Nippon Medical School Hospital /ID# 270254
Bunkyo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital Of JFCR /ID# 268342
Koto-ku, Tokyo, Japan · Recruiting
Universitair Medisch Centrum Utrecht /ID# 267660
Utrecht, Netherlands · Recruiting
Amsterdam UMC, Location VUmc /ID# 267670
Amsterdam, North Holland, Netherlands · Recruiting
Oslo Universitetssykehus Ulleval /ID# 275433
Oslo, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.